Immune checkpoint inhibitor-related acral vasculitis
Open Access
- 16 November 2018
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 120
Abstract
Commentary on « Ipilimumab induced vasculitis » by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resected stage III B/C melanoma. We report a similar case of acral vasculitis occurring with a combination of anti-CTLA-4 (tremelimumab) and anti-PD-L1 (durvalumab) prescribed for the management of a metastatic urothelial bladder cancer. In contrast to Padda A. et al., we observed a significant improvement with oral corticosteroids.Keywords
This publication has 5 references indexed in Scilit:
- Vasculitis associated with immune checkpoint inhibitors—a systematic reviewClinical Rheumatology, 2018
- Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapyAnnals of the Rheumatic Diseases, 2018
- Ipilimumab induced digital vasculitisJournal for ImmunoTherapy of Cancer, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockadeBMC Cancer, 2017